Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Mayo Clinic
Kivu Bioscience Inc.
Bayer
Children's Oncology Group
AstraZeneca
SEED Therapeutics, Inc.
MacroGenics
UNC Lineberger Comprehensive Cancer Center
Solve Therapeutics
University of Nebraska
Adela, Inc
Tanabe Pharma America, Inc.
M.D. Anderson Cancer Center
Northwestern University
Innolake Biopharm